ResultsIQ

ResultsIQ › Latest results › Blue Jet Healthcare Limited

Blue Jet Healthcare Limited Q4 FY26 results deck summary

NSE: BLUEJET · BSE: 544009

Results deck of 25 May 2026, summarised by AI from the filing.

Revenue from operations ₹2,347 mn in Q4 FY26, down 31.1% YoY from ₹3,404 mn, on negligible sales of one PI molecule.

Key takeaways

  1. Q4 revenue Revenue from operations ₹2,347 mn in Q4 FY26, down 31.1% YoY from ₹3,404 mn, on negligible sales of one PI molecule.
  2. PI recovery PI de-stocking and inventory normalization completed by the customer; robust revenues expected backed by orders in coming quarters.

Original filing on BSE

Blue Jet Healthcare Limited Q1 FY27 results

As filed: Revenue ₹293 cr (−17% year on year), EBITDA ₹98.1 cr (−20% year on year), PAT ₹78.3 cr (−14% year on year), EBITDA margin 33.5% (−90 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹235 cr (−31% year on year), EBITDA ₹71.3 cr (−49% year on year), PAT ₹64.3 cr (−42% year on year), EBITDA margin 30.4% (−1,000 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Other income 26% of PBT. Share price after the results: +17.2% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹192 cr (−39% year on year), EBITDA ₹46.9 cr (−62% year on year), PAT ₹40.2 cr (−59% year on year), EBITDA margin 24.4% (−1,000 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Profit fell 23% from last quarter. Share price after the results: −18.8% in 28 days (Nifty 500: −9.6%).
  • Q2 FY26: Revenue ₹165 cr (−21% year on year), EBITDA ₹56.0 cr (−20% year on year), PAT ₹52.0 cr (−10% year on year), EBITDA margin 33.9% (+29 bps). Score 6 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin rose 29 bps year on year. Other income 35% of PBT. Revenue fell 54% from last quarter. Share price after the results: −17.7% in 30 days (Nifty 500: −0.3%).
  • Q1 FY26: Revenue ₹355 cr (+118% year on year), EBITDA ₹122 cr (+184% year on year), PAT ₹91.0 cr (+139% year on year), EBITDA margin 34.4% (+799 bps). Score 85 of 100, Above trend. EBITDA margin rose 799 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 17% from last quarter. Share price after the results: −23.5% in 30 days (Nifty 500: −1.0%).
  • Q4 FY25: Revenue ₹340 cr (+85% year on year), EBITDA ₹140 cr (+164% year on year), PAT ₹110 cr (+182% year on year), EBITDA margin 41.2% (+1,000 bps). Score 100 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +24.0% in 30 days (Nifty 500: +2.5%).
  • Q3 FY25: Revenue ₹318 cr (+90% year on year), EBITDA ₹124 cr (+125% year on year), PAT ₹99.0 cr (+209% year on year), EBITDA margin 39.0% (+606 bps). Score 100 of 100, Above trend. EBITDA margin rose 606 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹208 cr (+15% year on year), EBITDA ₹70.0 cr (+13% year on year), PAT ₹58.0 cr (+21% year on year), EBITDA margin 33.7% (−60 bps). Score 55 of 100, In line with trend. EBITDA margin fell 60 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Blue Jet Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.